Physician profile
Arjun S Kanwal
NPI 1992200521
$11,087.45
in general payments reported to CMS, 2019-2025
15 companies · $10K in 2025
The $10K reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $97.66 · 2021: $80.76 · 2022: $250 · 2023: $180 · 2024: $416 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,160 · Food and Beverage: $1,380 · Consulting Fee: $1,020 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,160.00 |
| Food and Beverage | $1,379.81 |
| Consulting Fee | $1,020.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $9,788.60 | 2022-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $296.95 | 2021-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $253.43 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $133.81 | 2020-2025 | Farxiga |
| Astellas Pharma US INC | $99.00 | 2023 | |
| Novo Nordisk INC | $88.09 | 2025 | Wegovy |
| Amgen INC. | $78.10 | 2024-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $75.65 | 2024-2025 | Verquvo |
| Pfizer INC. | $68.17 | 2022-2024 | |
| Esperion Therapeutics, INC. | $60.48 | 2024-2025 | Nexletol |
| Abiomed | $45.58 | 2024-2025 | Impella |
| Lantheus Medical Imaging, INC. | $28.72 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $26.66 | 2024 | Arcalyst |
| Recor Medical INC | $25.76 | 2025 | Paradise Ultrasound Renal Denervation System |
| Scpharmaceuticals INC. | $18.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Kanwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.